Theralizumab
Theralizumab
Theralizumab (pronounced as Ther-a-liz-u-mab) is a monoclonal antibody designed for the treatment of multiple sclerosis.
Etymology
The name "Theralizumab" is derived from the Greek words "therapeia" meaning treatment and "zumab" is a suffix used in the names of humanized monoclonal antibodies.
Usage
Theralizumab is used in the treatment of relapsing-remitting multiple sclerosis (RRMS), a form of multiple sclerosis characterized by periods of new symptoms or relapses that develop over days or weeks and usually improve partially or completely. These relapses are followed by periods of months to years of relative quiet (remission) with no new signs of disease activity.
Mechanism of Action
Theralizumab works by targeting and depleting a specific subset of immune cells that contribute to the pathogenesis of multiple sclerosis. It binds to the CD52 antigen, a protein present on the surface of mature lymphocytes, but not on the stem cells from which these lymphocytes are derived.
Related Terms
External links
- Medical encyclopedia article on Theralizumab
- Wikipedia's article - Theralizumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski